Nektar Therapeutics (NKTR) Stock: From Low to High in 52 Weeks

Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Nektar Therapeutics’s current trading price is -31.02% away from its 52-week high, while its distance from the 52-week low is 222.35%. The stock’s price range over this period has fluctuated between $0.41 and $1.93. The company, operating within the financial sector, had a trading volume of approximately 1.6 million for the day, which was noticeably lower than the average daily share volume of 2.4 million over the last 3 months.

The market performance of Nektar Therapeutics’s stock has been harmonious in recent times. Over the last year, the company’s stock reached its highest point at $1.93 on 05/13/24, while the lowest value for the same duration was $0.41 on 11/13/23.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis

Nektar Therapeutics (NKTR) has experienced a quarterly rise of 6.40% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 244.75M and boasts a workforce of 137 employees.

Analyzing Trading Volume and Moving Average Trends

Based on Barchart.com data, the company’s moving average over the 100-day period was 1.2194, with a change in price of +0.5600. Similarly, Nektar Therapeutics recorded 2,464,497 in trading volume during the last 100 days, posting a change of +72.73%.

Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis

The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for NKTR stands at 1.83. Similarly, the long-term debt-to-equity ratio is also 1.68.

NKTR Stock Stochastic Average

Today’s raw stochastic average for Nektar Therapeutics over the last 50 days is 34.86%.This indicates a decrease from the raw stochastic average of the past 20 days, which was 85.33%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 68.20% and 63.57%, respectively.

NKTR Stock Price Performance Analysis

Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded an increase of 135.40%. However, over the last six months, the performance has been weaker by 126.58%. The price of NKTR increased 5.56% over the last 30 days. And in the last five days, it has surged by 13.68%.

Most Popular